HLHRUXO |
Phase Ib/II, clinical trial using ruxolitinib for treatment of patients with newly diagnosed or relapsed/refractory hemophagocytic lymphohistiocytosis (HLH) |
HLHRUXO |
Phase Ib/II, clinical trial using ruxolitinib for treatment of patients with newly diagnosed or relapsed/refractory hemophagocytic lymphohistiocytosis (HLH) |
Site Selection |
Study Overview |
Ten centers were selected to participate in the study during the initial site selection process. Selected sites have been notified by the NACHO Operations Center.
|
Clinical Coordinating Center
|
Operations & Data Coordinating Center
|